Patent Term Application for VYLOY (zolbetuximab-clzb), Patent No. 12,059,464 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

Open for Comments

FDA-2025-E-0872

Patent Term Application for VYLOY (zolbetuximab-clzb), Patent No. 12,059,464

Documents

Comments

Description

OPEN

Comment Period OpensMar 26, 2025

Comment Period ClosesJun 3, 2026

Type	Title	Posted	Comments	Status
Notice	Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY FR Doc: 2026-06478	Apr 3, 2026	--

CDER

Patent Term Application

Patent No. 12,059,464

Neal, Gerber & Eisenberg LLP

Astellas Pharma Inc

VYLOY (zolbetuximab-clzb)

TRON – Translationale Onkologie an der

Universitatesmedizin der Johannes